Latest News

In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.

Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?

Catch up on a variety of FDA news in radiology from the past week.

Catch up on the top radiology content of the past week.

Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.

Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.

Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.

For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.

In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.

In a study involving over 2,800 people who had brain MRI scans, researchers found that people in the most disadvantaged neighborhoods had 37 percent higher white matter hyperintensity volume (WMHV) on average in comparison to people in the least disadvantaged areas.

In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).

Amid the explosion of imaging volume, an emerging silver lining is increasing recognition from referring clinicians of the time and value radiologists provide to facilitate patient care.

In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.